Search

everythinglearnresearchcommunity

for

Search:↓

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.

Alopecia areata patients have fewer protective regulatory B cells, which may contribute to the disease.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Azathioprine can cause severe blood issues and hair loss, needing careful monitoring and possible discontinuation.

Higher TGF-β signaling may increase skin cancer risk in organ transplant recipients.

CD4 T cells need IFN-γ to cause hair loss in alopecia areata.

Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

Small molecule DMF improves psoriasis and multiple sclerosis, adult skin cells can be made to grow new hair, certain skin cells initiate hair growth, IL-17C controls gut health and can cause skin inflammation, and skin cells produce IL-17 that can lead to psoriasis.

Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.

Immune-epithelial interactions are crucial for tissue repair, but unchecked can cause diseases.

Combining triamcinolone acetonide with immunotherapy can help regrow hair in some alopecia totalis patients.

Microencapsulation helps protect and track therapeutic cells, showing promise for treating various diseases, but more work is needed to improve the technology.

DM and AA may share a common cause.

Co-trimoxazole may help treat autoimmune diseases.

ILC1-like cells can cause alopecia areata by attacking hair follicles.

Chitosan–hydroxyapatite biocomposites are promising for tissue engineering due to their safety and ability to support healing.

Alopecia areata involves immune system changes, especially in severe cases, with potential new treatment targets identified.

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

Blocking IL-8 can reduce skin rashes from cancer treatment.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Cytokine therapy is promising for treating skin conditions like vitiligo and psoriasis.

Targeted immune modulation can help achieve stable remission in alopecia areata.

Retinol may affect immune responses in people with frequent skin boils.

Methotrexate and azathioprine are equally effective and well-tolerated for treating lichen planopilaris.

IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.

Nanomedicines could offer better, longer-lasting psoriasis treatments with fewer side effects.